US Food and Drug Administration (USFDA) has completed inspection at Divi's Laboratories’ Unit-II at village Chippada, Bheemunipatnam District in the state of Andhra Pradesh (AP). The inspection was conducted from June 10 to 15, 2019.
This was a general CGMP inspection by the US-FDA. The inspection has been concluded with no 483 observations.
Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.